422 related articles for article (PubMed ID: 7055801)
21. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages.
Sone S; Fidler IJ
J Immunol; 1980 Dec; 125(6):2454-60. PubMed ID: 7430635
[TBL] [Abstract][Full Text] [Related]
22. Activation of macrophage cytostatic and cytotoxic activity in vitro by liposomes containing a new lipophilic muramyl peptide derivative, MDP-L-alanyl-cholesterol (MTP-CHOL).
Phillips NC; Moras ML; Chedid L; Petit JF; Tenu JP; Lederer E; Bernard JM; Lefrancier P
J Biol Response Mod; 1985 Oct; 4(5):464-74. PubMed ID: 3935756
[TBL] [Abstract][Full Text] [Related]
23. Preparation and antitumor effect of macrophage activating factor (MAF) encapsulated in liposomes bearing a monoclonal anti-human melanoma (A375) antibody.
Watanabe Y; Uchida E; Higuchi M; Imai Y; Osawa T
J Biol Response Mod; 1987 Oct; 6(5):556-68. PubMed ID: 3316511
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of liposome-encapsulated indomethacin in response against metastatic 3LL and B16F1 tumor cells.
Aliño SF; Unda FJ; Iruarrizaga A; Alfaro J; Hilario E; Pérez-Yarza G; Bobadilla M; Lejarreta M
Lab Invest; 1992 Jun; 66(6):671-9. PubMed ID: 1602737
[TBL] [Abstract][Full Text] [Related]
25. Delivery of macrophage-augmenting factors encapsulated in liposomes for destruction of tumor metastases.
Schroit AJ; Fidler IJ
Prog Clin Biol Res; 1982; 102 pt A():347-55. PubMed ID: 7167445
[No Abstract] [Full Text] [Related]
26. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.
Fidler IJ; Fogler WE; Brownbill AF; Schumann G
J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979
[TBL] [Abstract][Full Text] [Related]
27. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma.
Fidler IJ; Fan D; Ichinose Y
Invasion Metastasis; 1989; 9(2):75-88. PubMed ID: 2496047
[TBL] [Abstract][Full Text] [Related]
28. Macrophage activation for microbicidal activity against Leishmania major: inhibition of lymphokine activation by phosphatidylcholine-phosphatidylserine liposomes.
Gilbreath MJ; Nacy CA; Hoover DL; Alving CR; Swartz GM; Meltzer MS
J Immunol; 1985 May; 134(5):3420-5. PubMed ID: 3980997
[TBL] [Abstract][Full Text] [Related]
29. [Antitumoral activation of rat peritoneal macrophages by muramyl dipeptide in vitro].
Reisser D; Jeannin JF; Martin F
C R Seances Acad Sci III; 1982 Nov; 295(8):485-8. PubMed ID: 6819063
[TBL] [Abstract][Full Text] [Related]
30. Activation of tumoricidal properties in murine macrophages by intravenous injection of muramyl dipeptide encapsulated within liposomes as a treatment for spontaneous metastasis.
Fidler IJ; Poste G
Prog Clin Biol Res; 1981; 75B():257-67. PubMed ID: 7323097
[No Abstract] [Full Text] [Related]
31. [Antimetastatic effect of a liposome-enclosed analog of muramyl dipeptide].
Umanskiĭ VIu; Stefanov AV; Bondar' OP; Balitskiĭ KP; Pinchuk VG
Vopr Onkol; 1988; 34(4):433-8. PubMed ID: 2837005
[TBL] [Abstract][Full Text] [Related]
32. Liposome-encapsulated macrophage activation agents and active non-specific immunotherapy of neoplastic disease.
Poste G; Kirsh R
Prog Clin Biol Res; 1982; 102 pt A():309-19. PubMed ID: 7167443
[No Abstract] [Full Text] [Related]
33. Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin.
Gautam A; Waldrep JC; Densmore CL; Koshkina N; Melton S; Roberts L; Gilbert B; Knight V
Gene Ther; 2002 Mar; 9(5):353-7. PubMed ID: 11938455
[TBL] [Abstract][Full Text] [Related]
34. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice.
Koshkina NV; Kleinerman ES; Waidrep C; Jia SF; Worth LL; Gilbert BE; Knight V
Clin Cancer Res; 2000 Jul; 6(7):2876-80. PubMed ID: 10914737
[TBL] [Abstract][Full Text] [Related]
35. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice.
Yoo YC; Saiki I; Sato K; Azuma I
Vaccine; 1994 Feb; 12(2):175-60. PubMed ID: 8147100
[TBL] [Abstract][Full Text] [Related]
36. Chronic infection due to Mycobacterium intracellulare in mice: association with macrophage release of prostaglandin E2 and reversal by injection of indomethacin, muramyl dipeptide, or interferon-gamma.
Edwards CK; Hedegaard HB; Zlotnik A; Gangadharam PR; Johnston RB; Pabst MJ
J Immunol; 1986 Mar; 136(5):1820-7. PubMed ID: 3005400
[TBL] [Abstract][Full Text] [Related]
37. Rejection of intradermally injected syngeneic tumor cells from mice by specific elimination of tumor-associated macrophages with liposome-encapsulated dichloromethylene diphosphonate, followed by induction of CD11b(+)/CCR3(-)/Gr-1(-) cells cytotoxic against the tumor cells.
Takahashi T; Ibata M; Yu Z; Shikama Y; Endo Y; Miyauchi Y; Nakamura M; Tashiro-Yamaji J; Miura-Takeda S; Shimizu T; Okada M; Ueda K; Kubota T; Yoshida R
Cancer Immunol Immunother; 2009 Dec; 58(12):2011-23. PubMed ID: 19365632
[TBL] [Abstract][Full Text] [Related]
38. The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes.
Fidler IJ; Raz A; Fogler WE; Hoyer LC; Poste G
Cancer Res; 1981 Feb; 41(2):495-504. PubMed ID: 7004633
[TBL] [Abstract][Full Text] [Related]
39. Functional characteristics of the rat liver macrophage population after a single intravenous injection of liposome-encapsulated muramyl peptides.
Hoedemakers RM; Vossebeld PJ; Daemen T; Scherphof GL
J Immunother Emphasis Tumor Immunol; 1993 May; 13(4):252-60. PubMed ID: 8334109
[TBL] [Abstract][Full Text] [Related]
40. Antitumoral properties and reduced toxicity of LPS targeted to macrophages via normal or mannosylated liposomes.
Dumont S; Muller CD; Schuber F; Bartholeyns J
Anticancer Res; 1990; 10(1):155-60. PubMed ID: 2334121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
